POST-2
2016
Prevention of Syncope Trial 2
In 210 patients with recurrent vasovagal syncope, fludrocortisone did not significantly reduce the first recurrence of syncope over one year compared with placebo, although a benefit emerged once the dose had been stabilised.
Result
Efficacy: Time to first recurrence of syncope over 1 yearHR 0.69 (95% CI 0.46-1.03) · P = 0.069
Below 1 favours fludrocortisone, above 1 favours placebo.
Also reported: The prespecified 40 % relative risk reduction was not met. Restricted to the period after dose stabilisation, HR 0.51 (95 % CI 0.28–0.89; p=0.019).
- Subtopic
- Vasovagal syncope
- Design
- Double-blind, placebo-controlled RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Sheldon R, Raj SR, Rose MS, et al. J Am Coll Cardiol. 2016;68(1):1-9.doi 10.1016/j.jacc.2016.04.030
Discussion & critique
It formally missed its primary endpoint and the supportive analyses are post hoc, so the effect is fragile. It is nonetheless the largest randomised evidence for fludrocortisone and underpins its class-IIb place in young patients with low blood pressure.